SLU-PP-332

SLU-PP-332 Research Compound

SLU-PP-332 is a synthetic research compound developed as an agonist of the estrogen-related receptor family, including ERRα, ERRβ and ERRγ.

Estrogen-related receptors are nuclear receptors involved in the regulation of cellular metabolism, mitochondrial activity and energy-related gene expression. Published preclinical studies characterize SLU-PP-332 as a pan-ERR agonist, with particularly notable activity at ERRα.

In laboratory settings, SLU-PP-332 may be studied in areas including:

• ERRα, ERRβ and ERRγ signaling
• Nuclear receptor research
• Mitochondrial metabolism
• Cellular bioenergetics
• Oxidative metabolism
• Mitochondrial gene-expression pathways
• Metabolic signaling
• Chemical-probe characterization
• Structure-activity relationship research
• In-vitro metabolism and analytical characterization

Research has also examined SLU-PP-332 in cell and animal models involving mitochondrial function, skeletal-muscle oxidative pathways and metabolic regulation. These findings are preclinical and should not be interpreted as evidence of safety or effectiveness in humans.

More recent research has characterized SLU-PP-332 as a useful benchmark compound for studying ERR agonism, transcriptional signaling and structure-activity relationships.

Product Information

• Product: SLU-PP-332
• Classification: Synthetic small-molecule research compound
• Target: ERRα / ERRβ / ERRγ
• Primary Research Area: Mitochondrial and metabolic research
• Research Type: Laboratory, analytical and biochemical research
• Supplier: Peptides R US

Research Use Only

This product is offered solely for legitimate laboratory, analytical and scientific research purposes.

It is not intended for human or veterinary consumption or administration and is not intended to diagnose, treat, cure, mitigate or prevent any disease or medical condition.

No dosage, administration, therapeutic-use, performance-enhancement or human-use instructions are provided or implied.

I also would not describe SLU-PP-332 as FDA approved. An FDA substance search did not return an exact registered match for SLU-PP-332, while current published literature continues to characterize it as an experimental research compound.